Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Vall d'Hebron Institute of Oncology, Vall d'Hebron Institut de Recerca, Hebron University, Vall d'Hebron Hospital Universitari, Texas Oncology, Caris Life Sciences (United States), Cornell University, Masaryk Memorial Cancer Institute, Centre Jean Perrin, City Clinical Oncology Center, Institut Curie, Centre François Baclesse, Pyatigorsk Oncology Center, Institut Jules Bordet, Kaiser Permanente, Centre Hospitalier Universitaire de Tours, Bretonneau Hospital, Eisai (United States), Eisai (Japan), Eisai (United Kingdom), University of Leeds, St James's University Hospital